Let’s start up with the current stock price of CRISPR Therapeutics AG (CRSP), which is $149.72 to be very precise. The Stock rose vividly during the last session to $163.556 after opening rate of $152.19 while the lowest price it went was recorded $142.50 before closing at $147.54.
Recently in News on December 5, 2020, CRISPR Therapeutics and Vertex Present New Data for Investigational CRISPR/Cas9 Gene-Editing Therapy, CTX001™ at American Society of Hematology Annual Meeting and Exposition, Together With Publication in the New England Journal of Medicine. – Beta thalassemia: All seven patients were transfusion independent with 3 to 18 months of follow-up after CTX001 infusion -. You can read further details here
There is a secret stock that is LOADED with opportunity for savvy investors to make a fortune!
CRISPR Therapeutics AG had a pretty favorable run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $163.56 on 12/07/20, with the lowest value was $32.30 for the same time period, recorded on 03/16/20.
CRISPR Therapeutics AG (CRSP) full year performance was 106.88%
Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, CRISPR Therapeutics AG shares are logging -0.92% during the 52-week period from high price, and 363.53% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $32.30 and $151.11.
The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 4268370 for the day, which was evidently higher, when compared to the average daily volumes of the shares.
When it comes to the year-to-date metrics, the CRISPR Therapeutics AG (CRSP) recorded performance in the market was 145.83%, having the revenues showcasing 83.80% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 10.07B, as it employees total of 304 workers.
Market experts do have their say about CRISPR Therapeutics AG (CRSP)
During the last month, 11 analysts gave the CRISPR Therapeutics AG a BUY rating, 1 of the polled analysts branded the stock as an OVERWEIGHT, 5 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 2 of the polled analysts provided SELL rating.
According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 96.08, with a change in the price was noted +58.40. In a similar fashion, CRISPR Therapeutics AG posted a movement of +63.95% for the period of last 100 days, recording 979,808 in trading volumes.
Total Debt to Equity Ratio (D/E) can also provide valuable insight into the company’s financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders’ equity The total Debt to Equity ratio for CRSP is recording 0.00 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.00.
Technical breakdown of CRISPR Therapeutics AG (CRSP)
Raw Stochastic average of CRISPR Therapeutics AG in the period of last 50 days is set at 83.58%. The result represents improvement in oppose to Raw Stochastic average for the period of the last 20 days, recording 80.11%. In the last 20 days, the company’s Stochastic %K was 86.73% and its Stochastic %D was recorded 89.32%.
Bearing in mind the latest performance of CRISPR Therapeutics AG, several moving trends are noted. Year-to-date Price performance of the company’s stock appears to be pessimistic, given the fact the metric is recording 145.83%. Additionally, trading for the stock in the period of the last six months notably improved by 136.67%, alongside a boost of 106.88% for the period of the last 12 months. The shares increased approximately by 17.96% in the 7-day charts and went down by 44.88% in the period of the last 30 days. Common stock shares were driven by 83.80% during last recorded quarter.